Oncologists Spend Too Little Time With Patients, Too Much on EHR
The Medscape Oncologist Compensation Report 2018 reveals more about oncology practice than simple...
02:45
Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures
Among the new data on immunotherapy for lung cancer presented at the recent AACR meeting, the...
06:39
Checkpoint Inhibitors Have a Role for 'Virtually Every Patient'
After an 'extraordinary week' of advances in lung cancer, Dr Mark Kris explains why checkpoint...
05:35
'Oncology Done Right Is About Balance': Weighing IO Side Effects
When discussing checkpoint inhibitor adverse effects, Dr Mark Kris argues that we have to...
05:59
'Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer
Recent approval of rucaparib gives patients with ovarian cancer another new option for...
01:44
Stop Screening for Early Ovarian Cancer, USPSTF Says
There is no evidence that screening actually improves outcomes in ovarian cancer, according to a...
02:15
'100,000 Genomes' Project: Linking Genome Sequencing to Outcomes
Dr David Kerr shares thoughts on the 100,000 Genomes project linking whole genome sequencing to...
04:47
An Alternative to Dalteparin for Cancer-Related VTE
Dr David Kerr discusses a promising new study suggesting that oral edoxaban may be substituted...
03:40
Is Genotype Screening Needed Before Fluoropyrimidines?
Dr David Kerr on how the recent case for DPYD screening may be on (and off) mark in addressing...
04:40
A Moment to Reflect on Communicating Bad News to Patients
Dr David J. Kerr discusses the difficult task of delivering bad news to patients--and their often...
04:20
Combined Prognostic Factors Clarify Colorectal Cancer Risk
Dr David Kerr on how combining ploidy and stroma-tumor fraction can guide treatment decisions in...
04:30
Survey: Stark Disparities Exist in Global Oncologists' Workload
Dr David Kerr on a first-of-its-kind analysis revealing that much work is needed to alleviate the...
04:53
'False Hope' Over Immunotherapy? The Media's Misguided Effects
Dr Kathy Miller responds to a recent New York Times article documenting rare immunotherapy...
03:42
'Tremendous Loss' of a Giant in Psycho-Oncology
Dr Mark Kris pays tribute to a true giant in the field of oncology and his dear friend, Jimmie...
07:05
Is Aspirin the New (Old) Immunotherapy?
Dr David Kerr on how this time-tested drug enhances more complex and expensive immunotherapies.
03:39
Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma
Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and...
04:20
'Moving the Needle' in Oncology Workforce Diversity
Authors of a recent ASCO statement on diversity discuss their experiences and suggestions for...
20:16
Feb 16, 2018 This Week in Cardiology
ICD use in patients with CKD, PFO and peri-operative stroke, LV assist devices,...
11:55
Overlooked Biomarker May Predict Cancer Immunotherapy Response
Dr David Kerr on data showing that tumors with extensive aneuploidy may not benefit as much from...
04:18
Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+...
13:28
Lo último de Salud, hogar y consumo
2PM ET 04/19/2024 Newscast
Episodio
![Level Up Your Life: Mastering the Art of Gamification - [TPL] S2E205](https://img-static.ivoox.com/index.php?w=77&h=77&url=https://static-1.ivoox.com/audios/8/0/c/6/80c6d7ba2edbd70f3591ce84ee97df39_XXL.jpg)
Alana Kirk : Midlife coach
Episodio
Premium
Plus